miR‑219‑5p suppresses the proliferation and invasion of colorectal cancer cells by targeting calcyphosin

Wang,Quhui; Zhu,Lirong; Jiang,Yasu; Xu,Junfei; Wang,Feiran; He,Zhixian

doi:10.3892/ol.2017.5570

miR‑219‑5p suppresses the proliferation and invasion of colorectal cancer cells by targeting calcyphosin

Authors:
- Quhui Wang
- Lirong Zhu
- Yasu Jiang
- Junfei Xu
- Feiran Wang
- Zhixian He
View Affiliations

Affiliations: Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: January 4, 2017 https://doi.org/10.3892/ol.2017.5570
Pages: 1319-1324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are small non‑coding RNAs involved in an array of biological processes, and their dysregulation is associated with tumor development and progression. One such miRNA, miR‑219‑5p, is abnormally expressed in patients with colorectal cancer (CRC). In the present study, reverse transcription‑quantitative polymerase chain reaction was performed to measure miR‑219‑5p expression in cells from both CRC tumors, and surrounding healthy tissue. MTT and invasion assays were used to determine the role of miR‑219‑5p in regulating CRC cell proliferation and invasion, respectively. A luciferase assay was then performed to assess the binding of miR‑219‑5p to the CAPS gene that encodes calcyphosin protein. The present study confirmed that miR‑219‑5p expression is significantly downregulated in CRC tissue. miR‑219‑5p knockdown promoted the growth of HCT‑8 cells and increased the expression of calcyphosin protein (CAPS). On the other hand, overexpressing miR‑219‑5p inhibited HCT‑8 cell growth and invasion, and downregulated CAPS expression. In addition, CAPS was identified as the functional downstream target of miR‑219‑5p by directly targeting its 3'‑untranslated region. Therefore, miR‑219‑5p may function as a tumor suppressor by decreasing CAPS expression, and subsequently inhibit tumor proliferation and invasion. These results indicate that novel therapeutic strategies that increase miR‑219‑5p expression may be developed to treat CRC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
3	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
4	Sun Y, Wang L, Guo SC, Wu XB and Xu XH: High-throughput sequencing to identify miRNA biomarkers in colorectal cancer patients. Oncol Lett. 8:711–713. 2014.PubMed/NCBI
5	Cheng J, Deng R, Zhang P, Wu C, Wu K, Shi L, Liu X, Bai J, Deng M, Shuai X, et al: miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. Oncol Rep. 34:1923–1932. 2015.PubMed/NCBI
6	Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y, Zhang X, Tang B, Chen Y, Wang X, et al: miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α. J Clin Endocrinol Metab. 100:E204–E213. 2015. View Article : Google Scholar : PubMed/NCBI
7	Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D and Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 586:884–891. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lecocq R, Lamy F and Dumont JE: Pattern of protein phosphorylation in intact stimulated cells: Thyrotropin and dog thyroid. Eur J Biochem. 102:147–152. 1980. View Article : Google Scholar
9	Clément S, Dumont JE and Schurmans S: Loss of calcyphosine gene expression in mouse and other rodents. Biochem Biophys Res Commun. 232:407–413. 1997. View Article : Google Scholar : PubMed/NCBI
10	Lefort A, Lecocq R, Libert F, Lamy F, Swillens S, Vassart G and Dumont JE: Cloning and sequencing of a calcium-binding protein regulated by cyclic AMP in the thyroid. Embo J. 8:111–116. 1989.PubMed/NCBI
11	Nemoto Y, Ikeda J, Katoh K, Koshimoto H, Yoshihara Y and Mori K: R2D5 antigen: A calcium-binding phosphoprotein predominantly expressed in olfactory receptor neurons. J Cell Biol. 123:963–976. 1993. View Article : Google Scholar : PubMed/NCBI
12	Dong H, Li X, Lou Z, Xu X, Su D, Zhou X, Zhou W, Bartlam M and Rao Z: Crystal-structure and biochemical characterization of recombinant human calcyphosine delineates a novel EF-hand-containing protein family. J Mol Biol. 383:455–464. 2008. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Garzon R, Calin GA and Croce CM: MicroRNAs in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
15	Jiang Y, Yin L, Jing H and Zhang H: MicroRNA-219-5p exerts tumor suppressor function by targeting ROBO1 in glioblastoma. Tumour Biol. 36:8943–8951. 2015. View Article : Google Scholar : PubMed/NCBI
16	Sen R, Ghosal S, Das S, Balti S and Chakrabarti J: Competing endogenous RNA: The key to posttranscriptional regulation. ScientificWorldJournal. 2014:8962062014. View Article : Google Scholar : PubMed/NCBI
17	Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
18	Esquela-kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W and Qin H: miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 61:1447–1453. 2012. View Article : Google Scholar : PubMed/NCBI
20	Schee K and Ø and Flatmark K Fodstad: MicroRNAs as biomarkers in colorectal cancer. Am J Pathol. 177:1592–1599. 2010. View Article : Google Scholar : PubMed/NCBI
21	He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, Sung JJ and Yu J: MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 18:1491–1498. 2013.PubMed/NCBI
22	Kretsinger RH: Crystallographic studies of calmodulin and homologs. Ann N Y Acad Sci. 356:14–19. 1980. View Article : Google Scholar : PubMed/NCBI
23	de Bont JM, de Boer ML, Kros JM, Passier MM, Reddingius RE, Smitt PA, Luider TM and Pieters R: Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis. J Neuropathol Exp Neurol. 66:505–516. 2007. View Article : Google Scholar : PubMed/NCBI
24	Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Salinas A, De la Peña M González, Martín-Juan J, Corral J, García-Carbonero R, Carnero A and Paz-Ares L: Identification of proteomic signatures associated with lung cancer and COPD. J Proteomics. 89:227–237. 2013. View Article : Google Scholar : PubMed/NCBI
25	Partheen K, Levan K, Osterberg L and Horvath G: Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 42:2846–2854. 2006. View Article : Google Scholar : PubMed/NCBI
26	Li Z, Min W, Huang C, Bai S, Tang M and Zhao X: Proteomics-based approach identified differentially expressed proteins with potential roles in endometrial carcinoma. Int J Gynecol Cancer. 20:9–15. 2010. View Article : Google Scholar : PubMed/NCBI